Ocugen (NASDAQ:OCGN) Issues Earnings Results

Ocugen (NASDAQ:OCGN) announced its quarterly earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02), FiscalAI reports. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.89 million.

Here are the key takeaways from Ocugen’s conference call:

• OCU410 received FDA clearance to begin its Phase III ARMADA-3 trial in geographic atrophy, along with RMAT designation. The approximately 237-patient global study is expected to start by September 2026, supported by Phase II data showing a 31% reduction in lesion growth at the optimal dose.
• Ocugen expects several major clinical catalysts, including an interim decision for OCU410ST in Stargardt disease in the third quarter of 2026 and top-line data for OCU400 and OCU410ST in the first half of 2027. Management continues to target three BLA submissions by 2028.
• Enrollment is complete in the 140-patient Phase III liMeliGhT trial for OCU400 in broad retinitis pigmentosa, with top-line data expected in the first quarter of 2027. The company also completed manufacturing qualification batches intended to support potential BLA filings and commercial supply.
• Ocugen closed a $130 million convertible notes financing, reporting $100.4 million in cash, cash equivalents, and restricted cash at June 30, which management says extends its runway into 2028. It also signed a binding term sheet granting Roots Pharmaceutical and Al-Dhow International exclusive OCU400 rights in the Middle East and North Africa.
• Operating expenses increased to $17.9 million in the quarter from $15.2 million a year earlier, while quarterly net loss widened to $0.07 per share from $0.05. Management is evaluating additional financing, warrant exercises, business-development transactions, and a potential share authorization increase, creating possible future dilution.

Ocugen Stock Up 2.8%

Shares of OCGN traded up $0.04 during mid-day trading on Friday, reaching $1.27. The company’s stock had a trading volume of 1,299,733 shares, compared to its average volume of 7,394,878. Ocugen has a 1 year low of $0.96 and a 1 year high of $2.73. The company has a market cap of $432.37 million, a price-to-earnings ratio of -5.31 and a beta of 2.21. The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of 4.17. The business has a fifty day moving average of $1.34 and a 200 day moving average of $1.57.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OCGN. Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Canaccord Genuity Group decreased their price objective on shares of Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Weiss Ratings downgraded shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Insider Activity at Ocugen

In other news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was acquired at an average cost of $1.23 per share, for a total transaction of $25,830.00. Following the completion of the acquisition, the chief financial officer owned 521,000 shares in the company, valued at approximately $640,830. The trade was a 4.20% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.95% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ocugen

A number of large investors have recently bought and sold shares of the business. SmartHarvest Portfolios LLC bought a new position in Ocugen during the fourth quarter valued at about $31,000. NewEdge Advisors LLC raised its stake in shares of Ocugen by 198.0% in the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock valued at $36,000 after acquiring an additional 24,460 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock worth $36,000 after purchasing an additional 13,326 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Ocugen during the fourth quarter valued at approximately $38,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Ocugen by 28,222.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company’s stock valued at $41,000 after purchasing an additional 30,198 shares during the period. 10.27% of the stock is currently owned by institutional investors.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy associated with dry age-related macular degeneration. The trial is expected to start this quarter, and the program received FDA Regenerative Medicine Advanced Therapy designation, which may support priority review and accelerated approval. Ocugen Provides Business Update with Second Quarter 2026 Financial Results
• Positive Sentiment: Ocugen closed a $130 million convertible senior notes offering, generating approximately $112.5 million in net proceeds and extending its cash runway into 2028. About $32.7 million was used to retire higher-cost Avenue Capital debt. The financing reduces near-term liquidity risk, although the convertible structure may create future dilution. Ocugen Reports Q2 2026 Results
• Positive Sentiment: The company signed a binding term sheet to negotiate an exclusive OCU400 license in the Middle East and North Africa. The agreement could provide an upfront payment, up to $255 million in sales milestones, and a 22% royalty on net sales.
• Positive Sentiment: Ocugen remains on track for important data and regulatory milestones: OCU400 retinitis pigmentosa results are expected in the first quarter of 2027, OCU410ST Stargardt disease results in the second quarter, and management is targeting as many as three biologics license applications by 2028. Ocugen Targets Three BLAs by 2028
• Neutral Sentiment: Second-quarter revenue was $1.49 million, exceeding the $0.89 million consensus estimate, but revenue remains modest and primarily reflects collaborative arrangements.
• Negative Sentiment: Ocugen reported a loss of $0.07 per share, wider than the $0.05 consensus estimate and the year-ago loss. Operating expenses increased to $17.9 million from $15.2 million, while the accumulated deficit reached $452.1 million, underscoring continued cash burn and execution risk. Ocugen Reports Q2 Loss

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.